vTv Therapeutics Inc. carries no debt; cash flow comfortably covers obligations.

vTv Therapeutics Inc.'s free cash flow has increased -0.21% from $-25.31M last year to $-25.25M, signaling increasing performance

vTv Therapeutics Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

vTv Therapeutics Inc.'s debt has decreased relative to shareholder equity from 0.01 last year to 0.00 today, signaling strengthened financials

vTv Therapeutics Inc. has negative EBITDA, making leverage ratio unreliable

vTv Therapeutics Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

vTv Therapeutics Inc.'s profit margin has increased (-100.34%) in the last year from -1.82K% to 6.11%, signaling increasing performance

vTv Therapeutics Inc.'s short-term assets of $89.89M exceed its short-term liabilities of $6.64M

vTv Therapeutics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

vTv Therapeutics Inc.'s return on equity of 3.96%, is lower than 15.00%, indicating bad performance

vTv Therapeutics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

vTv Therapeutics Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

vTv Therapeutics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

vTv Therapeutics Inc. has negative free cash flow, indicating cash burn

vTv Therapeutics Inc.'s yearly earnings has decreased 46.11% since last year from $-18.46M to $-26.97M, signaling decreasing performance

vTv Therapeutics Inc.'s yearly revenue has decreased -100.00% since last year from $1.02M to $0.00, signaling decreasing performance

ROIC -3.31% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

vTv Therapeutics Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

vTv Therapeutics Inc. had revenue growth in only 1.00 out of 5 years, indicating inconsistent revenue performance

vTv Therapeutics Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

vTv Therapeutics Inc. has insufficient data to evaluate this check.

vTv Therapeutics Inc. has an earnings yield of 0.76%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

vTv Therapeutics Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

vTv Therapeutics Inc. has an EV/EBITDA ratio of 8.78x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

vTv Therapeutics Inc. has insufficient data to evaluate this check.

vTv Therapeutics Inc. has a PEG-ratio over 1 which is considered overvalued

vTv Therapeutics Inc. has a price-to-book ratio of 3.28x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

vTv Therapeutics Inc. has a price-to-sales ratio of 2.49x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue